AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

AbbVie’s beat Wall Street’s estimates for its top- and bottom-lines in the second quarter, boosted by sales of Skyrizi and ...

That's because AbbVie is a solid dividend payer, with a recent dividend yield of 3.4%. It's a dividend grower, too. Its total ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...